New genetic research shows why some people develop deadly Huntington's disease earlier than others. The findings could lead to better treatments.

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and ... additional avenues for treatment. While it's known ...

LEXINGTON, Mass. - uniQure N.V. (NASDAQ: NASDAQ:QURE), a gene therapy company with a market capitalization of $767 million, ...

Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two years.

Could viral infections play a role in Huntington's disease? Research suggests Apolipoprotein B mRNA editing catalytic ...

More information: Thai B. Nguyen et al, Aberrant splicing in Huntington's disease accompanies disrupted TDP-43 activity and altered m6A RNA modification, Nature Neuroscience (2025). DOI: 10.1038 ...

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on QURE stock, giving a Buy rating on January 21.Invest with ...

Subtle signs of neurodegeneration can be detected in blood, CSF, and neuroimaging, up to 20 years before the motor symptoms ...

Huntington's disease kills a population of cells called ... He adds that slowing down certain DNA-maintenance processes with a molecular therapy might slow down DNA-repeat expansion by allowing ...

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on QURE stock, giving a Buy rating on January 27.Maximize Your ...

The HDBuzz team caught up with editor emeritus and Huntington's disease specialist, Prof Ed Wild to hear his thoughts on what ...